當前位置：   首頁(yè) > 需求大廳

 >  特色服務(wù) 

求購“Saccharin Sodium” BP2017 和BP2018的藥典標準各一份   [更多]

1.Nihon Yakurigaku Zasshi. 2013 Jul;142(1):39-46. doi: 10.1254/fpj.142.39. Pharmacological and clinical properties of AIMIX combination tablets LD&HD, fixed-dose combination of irbesartan and amlodipine besilate. 2.Am J Cardiovasc Drugs. 2013 Apr;13(2):141-50. doi: 10.1007/s40256-013-0014-7. Irbesartan/amlodipine: a review of its use in adult patients with essential hypertension not adequately controlled with monotherapy. 3.Clin Ther. 2012 Aug;34(8):1705-19. doi: 10.1016/j.clinthera.2012.06.026. Epub 2012 Jul 30. I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study. 4.Clin Ther. 2012 Aug;34(8):1720-34.e3. doi: 10.1016/j.clinthera.2012.07.001. Epub 2012 Jul 30. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study. 5.Am J Cardiovasc Drugs. 2013 Apr;13(2):141-50. doi: 10.1007/s40256-013-0014-7. Irbesartan/amlodipine: a review of its use in adult patients with essential hypertension not adequately controlled with monotherapy. 6J Cardiol. 2019 Mar 20. pii: S0914-5087(19)30053-X. doi: 10.1016/j.jjcc.2019.03.001. [Epub ahead of print] Arginine vasopressin antagonism in heart failure: Current status and possible new directions. Goldsmith SR1. 7.Metabolism of Peptide Drugs and Strategies to Improve their Metabolic Stability 8.Expert Rev Neurother. 2017 Jan;17(1):59-75. Epub 2016 Oct 20. Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology. Tramutola A1, Arena A1,   [更多]

1.丙氨酰谷氨酰胺及其注射液的研究開(kāi)發(fā) 2.A prospective multicentre study on the treatment of cardiovascular risk factors and claudication symptoms in patients with peripheral artery disease (the IDOMENEO study). Cimminiello C, Arpaia G, Polo Friz H, Boracchi P, Marano G, Spezzigu G, Visonà A. Vasa. 2015 Sep;44(5):371-9. doi: 10.1024/0301-1526/a000456. 3.2013 International Conference on Materials Engineering, ICMEN 2013 4.Orientation of substitution in the aromatic series. XVIII. Sulfonation of phenol by chlorosulfonic acid in solvents 5.Mechanism of reaction of chlorosulfonic acid with some aromatic compounds 6.Arzneimittelforschung. 1982;32(3):248-51. In vitro--in vivo correlation, a time scaling problem? Basic considerations on in vitro dissolution testing. 7.Oral treatment with the Crataegus special extract WS 1442 inhibits cardiac hypertrophy in rats with DOCA-salt or aortic banding induced hypertension   [更多]

1.Nakashima M, Morita J, Aizawa K. Pharamacokinetics and safety of tebipenem pivoxil fine granules, an oral carbapenem antibiotic, in healthy male volunteers. Jpn J Chemother. 2009;57(S–1):90–94 2.Baba S, Yamanaka N, Suzuki K, et al. Clinical efficacy, safety and PK-PD analysis of tebipenem pivoxil in a phase II clinical trial in otolaryngological infections. Jpn J Antibiot. 2009;62:155–177 3.Sunakawa K. Pharmacological properties and clinical performance of the novel oral carbapenem antimicrobial drug, “Tebipenem pivoxil” (Orapenem fine granules 10% for pediatric use). Jpn J Chemother. 2009;57:279–294 4.Yamanaka N, Furukawa M, Furuya, et al. Clinical efficacy of tebipenem pivoxil (ME1211), a novel oral carbapenem, in otolaryngological infections, a Phase II clinical trial (1). 45th Intersci Conf Antimicrob Agents Chemother (ICAAC) 2005; Abstract L-577 5.Iwata S, Ouchi K, Iwata N, et al. An open clinical study of tebipenem pivoxil in children with bacterial pneumonia. Jpn J Chemother. 2009;57(S–1):137–150   [更多]

求DOF 2019年1-3期文獻   [更多]

標題：求購克拉霉素緩釋片USP41標準 詳細要求： 需求名稱(chēng)：克拉霉素緩釋片標準 具體要求：USP42 要求時(shí)間：請在2019年05月15日之前 交稿方式：直接點(diǎn)擊交稿在線(xiàn)交稿就是了，我會(huì )每天過(guò)來(lái)看的，謝謝各位藥智的戰友們   [更多]

① 從任務(wù)主手中獲取指定企業(yè)的年報文件， ② 將年報中的相應數據填入相應表格，年報中沒(méi)有的數據表格相應內容不做填寫(xiě)， ③ 要求仔細認真，熟悉英文或對翻譯工具的熟練使用， ④ 價(jià)格215元完成已有的86份年報數據提取(≈2.5元/份)（填寫(xiě)完了審核通過(guò)，每個(gè)年報要求把所有產(chǎn)品銷(xiāo)售額收集填寫(xiě)完）， ⑤ 如若審核發(fā)現有填錯，填漏；以每填錯，填漏一個(gè)數據1元計量扣除賞金。   [更多]

求歐洲藥典關(guān)于B19病毒檢測方法的技術(shù)方法及要求，214頁(yè)原文。如有其它各國藥典標準對比則更好。   [更多]

ID：嘻嘻嘻嘿嘿嘿，領(lǐng)取賞金；處理統計之后藥智網(wǎng)未收載的說(shuō)明書(shū)數量為36條，已收載的說(shuō)明書(shū)條數為43條，總的賞金=36*5+43*3=309   [更多]

1、Atropine and scopolamine premedication – Pharmacological aspects and present use in Finland 2、Identification and purity test of heparin by NMR - a summary of two years' experience at the Medical Products Agency By: McEwen I; Amini A; Olofsson I M 3、Atti della Accademia Nazionale dei Lincei, Classe di Scienze Fisiche, Matematiche e Naturali, Rendiconti 4、49-12 Metabolic Fate of Triethylenetetramine dihydrochloride (Trientine hydrochloride, TJA-250) 1. Absorption, Distribution and Excretion in Rats after Single … S Takeda, E Ono, Y Matsuzaki… - Oyo Yakuri …, 1995 - [Sendai, Japan: Oyo Yakuri … 5、49-13 Metabolic Fate of Triethylenetetramine dihydrochloride (Trientine hydrochloride, TJA-250) 2. Metabolism study in Rats Using 14C-TJA 250 S Takeda, E Ono, Y Wakui… - Oyo Yakuri …, 1995 - [Sendai, Japan: Oyo Yakuri …   [更多]